1-5 of 5
Shenghua Wen
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma

Nicolas Floc'h, Susan Ashton, Douglas Ferguson, Paula Taylor, Larissa S. Carnevalli, Adina M. Hughes, Emily Harris, Maureen Hattersley, Shenghua Wen, Nicola J. Curtis, James E. Pilling, Lucy A. Young, Kim Maratea, Elizabeth J. Pease, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2019) 18 (5): 909–919.
https://doi.org/10.1158/1535-7163.MCT-18-0577
Published: 01 May 2019
View articletitled, Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma
Open the PDF for Modeling Dose and Schedule Effects of AZD2811 Nanoparticles Targeting Aurora B Kinase for Treatment of Diffuse Large B-cell Lymphoma in another window
Includes: Supplementary data
Journal Articles

Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles

Nicolas Floc'h, Susan Ashton, Paula Taylor, Dawn Trueman, Emily Harris, Rajesh Odedra, Kim Maratea, Nicola Derbyshire, Jacqueline Caddy, Vivien N. Jacobs, Maureen Hattersley, Shenghua Wen, Nicola J. Curtis, James E. Pilling, Elizabeth J. Pease, Simon T. Barry
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2017) 16 (6): 1031–1040.
https://doi.org/10.1158/1535-7163.MCT-16-0580
Published: 01 June 2017
View articletitled, Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles
Open the PDF for Optimizing Therapeutic Effect of Aurora B Inhibition in Acute Myeloid Leukemia with AZD2811 Nanoparticles in another window
Includes: Supplementary data
Journal Articles

AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies

Garrett W. Rhyasen, Maureen M. Hattersley, Yi Yao, Austin Dulak, Wenxian Wang, Philip Petteruti, Ian L. Dale, Scott Boiko, Tony Cheung, Jingwen Zhang, Shenghua Wen, Lillian Castriotta, Deborah Lawson, Michael Collins, Larry Bao, Miika J. Ahdesmaki, Graeme Walker, Greg O'Connor, Tammie C. Yeh, Alfred A. Rabow, Jonathan R. Dry, Corinne Reimer, Paul Lyne, Gordon B. Mills, Stephen E. Fawell, Michael J. Waring, Michael Zinda, Edwin Clark, Huawei Chen
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2016) 15 (11): 2563–2574.
https://doi.org/10.1158/1535-7163.MCT-16-0141
Published: 01 November 2016
View articletitled, AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies
Open the PDF for AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies in another window
Includes: Supplementary data
Journal Articles

Abstract B150: Identifying tolerable schedules for targeted anti-cancer agents by applying ordered logistic regression modeling to empirical pathology scores in mice

Francis Gibbons, Shenghua Wen, Prasad Nadella
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B150.
https://doi.org/10.1158/1535-7163.TARG-15-B150
Published: 01 December 2015
View articletitled, Abstract B150: Identifying tolerable schedules for targeted anti-cancer agents by applying ordered logistic regression modeling to empirical pathology scores in mice
Journal Articles

A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models

Jeffrey L. Brown, Z. Alexander Cao, Maria Pinzon-Ortiz, Jane Kendrew, Corinne Reimer, Shenghua Wen, Joe Q. Zhou, Mohammad Tabrizi, Steve Emery, Brenda McDermott, Lourdes Pablo, Patricia McCoon, Vahe Bedian, David C. Blakey
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2010) 9 (1): 145–156.
https://doi.org/10.1158/1535-7163.MCT-09-0554
Published: 12 January 2010
View articletitled, A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models
Open the PDF for A Human Monoclonal Anti-ANG2 Antibody Leads to Broad Antitumor Activity in Combination with VEGF Inhibitors and Chemotherapy Agents in Preclinical Models in another window
Includes: Supplementary data